Cenisertib is primarily investigated for its potential in cancer therapy, particularly targeting Aurora kinases, which play a critical role in cell division. Its application is focused on inhibiting these kinases to disrupt the proliferation of cancer cells, making it a candidate for treating various malignancies. Research has explored its efficacy in conditions such as acute myeloid leukemia (AML), multiple myeloma, and solid tumors. By selectively targeting overactive kinases, it aims to induce apoptosis in cancer cells while minimizing damage to healthy tissues. Clinical trials are ongoing to assess its safety, dosage, and effectiveness, with the goal of developing it as a targeted therapeutic option for patients with limited treatment alternatives.